Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E,Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the…
Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A, White I, and ODYSSEY trial team Published in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019
Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019
Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830
Authors: Tierrablanca LE, Ochalek J, Ford D, et al; for BREATHER (PENTA 16) Trial Group Published in: Medicine (Baltimore). 2018;97(5):e9698 Objectives To analyze the cost effectiveness of short-cycle therapy (SCT), where patients take…
Authors: Turkova A, Moore CL, Butler K, et al. for BREATHER (PENTA 16) Trial Group. Published in: PLos One. 2018;13(4):e0196239. Background Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing…
Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22
Authors: Moore CL, Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34
Authors: Bernays S, Namukwaya S, Mupambireyi Z, Nanduudu A, Mujuru H, Turkova A, Gibb DM, Seeley J, and the ODYSSEY Trial Team. Published in: 10th International Workshop on HIV Pediatrics,…
Authors: Turkova A, Bollen P, Kaudha E, et al. The ODYSSEY Trial Team Published in: Oral Presentation at 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018
Despite great advances in pediatric HIV care, rates and the extent of full disclosure of HIV status to infected children remain low especially in resource-constrained setting. The World Health Organisation…
Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people's perspectives on the complex host of social…
Author: Butler K, Inshaw J, Ford D, et al. Published in: Health Technol Assess. 2016;20(49):1-108. Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents…
Author: The BREATHER (PENTA 16) Trial Group Published in: Lancet HIV. 2016;3(9):e421-430 Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends,…
Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group. Published in: AIDS. 2016;30(7):1075-81. Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of…
Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68 Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young…
Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team. Published in: JAIDS 2015;70(1):42-53 Background The PENPACT-1 trial compared virologic thresholds to determine when to switch…